Valore20212022202320242025TTMSpese di vendita, generali e amministrative——————Ricerca e sviluppo——————Reddito operativo——————Proventi non operativi, Totale——————Oneri finanziari, al netto degli interessi capitalizzati——————Proventi non operativi, esclusi gli oneri finanziari——————Entrate/uscite straordinarie——————Utile al lordo delle imposte——————Quota di utile——————Imposte——————Interessi di minoranza——————Altri proventi/oneri al netto delle imposte——————Utile netto al lordo delle attività cessate——————Attività cessate——————Utile netto——————Regolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari——————Utile base per azione (EPS base)——————Utile diluito per azione (EPS diluito)——————Numero medio di azioni ordinarie in circolazione——————Azioni diluite in circolazione——————EBITDA——————EBIT——————Costo del fatturato——————Altri costi del venduto——————Ammortamento e svalutazione (liquidità)——————
Evotec SE - American Depositary Shares each representing 1/2 of
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology.